Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iRelate: PET Tracers for T Cell Evaluation in NSCLC
NCT06457789Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluorine f 18 ara-g and crefmirlimab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoints: Spatial correlation of PET uptake of [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab at 2 months and Strength of correlation between the presence of CD8+ cells and T cell activation features with preoperative PET uptake at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
fluorine f 18 ara-gcrefmirlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06457789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457789.